LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Ruxolitinib dosing for acute graft-versus-host disease in a pediatric patient receiving continuous renal replacement therapy.

    Chen, Teaghan T / David, Alexandria P / Gordon, Sharon E / McLaughlin, Laura

    Pediatric blood & cancer

    2023  Volume 71, Issue 1, Page(s) e30754

    MeSH term(s) Humans ; Child ; Continuous Renal Replacement Therapy ; Nitriles ; Pyrimidines ; Graft vs Host Disease/drug therapy ; Graft vs Host Disease/etiology ; Hematopoietic Stem Cell Transplantation ; Retrospective Studies ; Acute Disease
    Chemical Substances ruxolitinib (82S8X8XX8H) ; Nitriles ; Pyrimidines
    Language English
    Publishing date 2023-10-30
    Publishing country United States
    Document type Letter
    ZDB-ID 2131448-2
    ISSN 1545-5017 ; 1545-5009
    ISSN (online) 1545-5017
    ISSN 1545-5009
    DOI 10.1002/pbc.30754
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1131: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.

    Chen, Teaghan T / David, Alexandria P / Barthelmess, Erin K / MacBrayne, Christine E

    Pediatric blood & cancer

    2023  Volume 70, Issue 11, Page(s) e30608

    Abstract: Background: Letermovir (LTV), an antiviral with exclusive activity against Cytomegalovirus (CMV), is approved for prophylaxis of CMV infection and disease in adult hematopoietic cell transplant (HCT) patients. The use of LTV in the pediatric HCT ... ...

    Abstract Background: Letermovir (LTV), an antiviral with exclusive activity against Cytomegalovirus (CMV), is approved for prophylaxis of CMV infection and disease in adult hematopoietic cell transplant (HCT) patients. The use of LTV in the pediatric HCT population is off-label, and has limited literature to support its use.
    Procedure: This was a single-center, retrospective, matched (1:1 LTV:non-LTV) cohort study of allogeneic HCT recipients transplanted at Children's Hospital Colorado from 2015 to 2022. The primary endpoint was clinically significant CMV DNAemia (defined as a CMV viral load >1000 copies/mL or any CMV DNAemia leading to preemptive treatment) through 6 months post transplant. Secondary outcomes included time to clinically significant CMV DNAemia, drug adverse effects, and dose adjustments of concomitant cyclosporine and voriconazole (known drug interactions).
    Results: We compared 41 patients who received LTV prophylaxis to 41 patients who received no CMV prophylaxis. There was less clinically significant CMV DNAemia through D+180 in the LTV group (9.8% vs. 17.0%, p = .33). Overall, LTV was well tolerated, and 87.8% of patients experienced no adverse effects related to the drug. There was no observed pattern in LTV effect on cyclosporine serum concentrations, but LTV was associated with decreased voriconazole trough levels.
    Conclusions: In this retrospective study, the use of LTV prophylaxis in pediatric stem cell patients was associated with reduced clinically significant CMV DNAemia through D+180.
    MeSH term(s) Adult ; Humans ; Child ; Cytomegalovirus ; Retrospective Studies ; Hematopoietic Stem Cell Transplantation/adverse effects ; Cohort Studies ; Voriconazole ; Cytomegalovirus Infections/etiology ; Cytomegalovirus Infections/prevention & control ; Cytomegalovirus Infections/drug therapy ; Antiviral Agents/therapeutic use ; Antiviral Agents/adverse effects ; Cyclosporins/pharmacology ; Cyclosporins/therapeutic use ; Transplant Recipients
    Chemical Substances letermovir (1H09Y5WO1F) ; Voriconazole (JFU09I87TR) ; Antiviral Agents ; Cyclosporins
    Language English
    Publishing date 2023-08-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2131448-2
    ISSN 1545-5017 ; 1545-5009
    ISSN (online) 1545-5017
    ISSN 1545-5009
    DOI 10.1002/pbc.30608
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1131: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top